Page 1 | Search Results | Blood | American Society of Hematology

1-7 of 7

Sort by

Sort Order Select

Journal Articles

TET2 Mutations Are Not Specific for Certain MPN Entities but More Likely Seem to Indicate Disease Progression.

Susanne Schnittger, PhD, Claudia Tschulik, Nicole Wendland, Sonja Schindela, Frank Dicker, PhD, Wolfgang Kern, MD, Torsten Haferlach, MD, Claudia Haferlach, MD

Blood (2009) 114 (22): 438.

https://doi.org/10.1182/blood.V114.22.438.438

Published: 2009

Journal Articles

Minimal residual disease levels assessed by NPM1 mutation–specific RQ-PCR provide important prognostic information in AML

Susanne Schnittger, Wolfgang Kern, Claudia Tschulik, Tamara Weiss, Frank Dicker, Brunangelo Falini, Claudia Haferlach, Torsten Haferlach

Blood (2009) 114 (11): 2220–2231.

https://doi.org/10.1182/blood-2009-03-213389

Published: 2009

Journal Articles

Analysis of Genetic Variants and Expression Levels of Human Organic Cation Transporter 1 (HOCT1) and Genetic Variants in MDR1 in CML: Weak Associations Were Detected but a Major Role in Clinical Response to Imatinib Resistance Is Unlikely

Susanne Schnittger, PhD, Sonja Rauhut, Claudia Tschulik, Madlen Ulke, Wolfgang Kern, MD, Claudia Haferlach, MD, Torsten Haferlach, MD

Blood (2008) 112 (11): 3203.

https://doi.org/10.1182/blood.V112.11.3203.3203

Published: 2008

Journal Articles

WT1 Expression as Follow up Marker in CML: Low Impact and Sensitivity Compared to BCR-ABL Specific RQ-PCR but High Impact for Detection of New Aberrant Clones in BCR-ABL Negative Follow up Samples

Susanne Schnittger, PhD, Claudia Haferlach, MD, Claudia Tschulik, Wolfgang Kern, MD, Torsten Haferlach, MD

Blood (2008) 112 (11): 4250.

https://doi.org/10.1182/blood.V112.11.4250.4250

Published: 2008

Journal Articles

Minimal Residual Disease Assessed by NPM1 Mutation Specific RQ-PCR Is the Most Relevant Prognostic Parameter in NPM1-Mutated AML and Highly Useful to Guide Therapy

Susanne Schnittger, PhD, Wolfgang Kern, MD, Tamara Weiss, Claudia Tschulik, Frank Dicker, PhD, Claudia Haferlach, MD, Torsten Haferlach, MD

Blood (2008) 112 (11): 698.

https://doi.org/10.1182/blood.V112.11.698.698

Published: 2008

Journal Articles

Nucleophosmin gene mutations are predictors of favorable prognosis in acute myelogenous leukemia with a normal karyotype

Susanne Schnittger, Claudia Schoch, Wolfgang Kern, Cristina Mecucci, Claudia Tschulik, Massimo F. Martelli, Torsten Haferlach, Wolfgang Hiddemann, Brunangelo Falini

Blood (2005) 106 (12): 3733–3739.

https://doi.org/10.1182/blood-2005-06-2248

Published: 2005

Journal Articles

Nucleophosmin Gene Mutations Are Predictors of Favourable Prognosis in Acute Myeloid Leukemia with a Normal Kayotype and Can Be Used as a New Marker for Quantitative PCR To Detect Minimal Residual Disease.

Susanne Schnittger, PhD, Claudia Schoch, MD, Wolfgang Kern, MD, Christina Mecucci, MD, PhD, Claudia Tschulik, Massimo F. Martelli, MD, Wolfgang Hiddemann, MD, Torsten Haferlach, MD, Brunangelo Falini, MD

Blood (2005) 106 (11): 223.

https://doi.org/10.1182/blood.V106.11.223.223

Published: 2005

NARROW

TET2 Mutations Are Not Specific for Certain MPN Entities but More Likely Seem to Indicate Disease Progression.

Minimal residual disease levels assessed by NPM1 mutation–specific RQ-PCR provide important prognostic information in AML

Analysis of Genetic Variants and Expression Levels of Human Organic Cation Transporter 1 (HOCT1) and Genetic Variants in MDR1 in CML: Weak Associations Were Detected but a Major Role in Clinical Response to Imatinib Resistance Is Unlikely

WT1 Expression as Follow up Marker in CML: Low Impact and Sensitivity Compared to BCR-ABL Specific RQ-PCR but High Impact for Detection of New Aberrant Clones in BCR-ABL Negative Follow up Samples

Minimal Residual Disease Assessed by NPM1 Mutation Specific RQ-PCR Is the Most Relevant Prognostic Parameter in NPM1-Mutated AML and Highly Useful to Guide Therapy

Nucleophosmin gene mutations are predictors of favorable prognosis in acute myelogenous leukemia with a normal karyotype

Nucleophosmin Gene Mutations Are Predictors of Favourable Prognosis in Acute Myeloid Leukemia with a Normal Kayotype and Can Be Used as a New Marker for Quantitative PCR To Detect Minimal Residual Disease.

Email alerts

ASH Publications

American Society of Hematology

TET2 Mutations Are Not Specific for Certain MPN Entities but More Likely Seem to Indicate Disease Progression.

Minimal residual disease levels assessed by NPM1 mutation–specific RQ-PCR provide important prognostic information in AML

Analysis of Genetic Variants and Expression Levels of Human Organic Cation Transporter 1 (HOCT1) and Genetic Variants in MDR1 in CML: Weak Associations Were Detected but a Major Role in Clinical Response to Imatinib Resistance Is Unlikely

WT1 Expression as Follow up Marker in CML: Low Impact and Sensitivity Compared to BCR-ABL Specific RQ-PCR but High Impact for Detection of New Aberrant Clones in BCR-ABL Negative Follow up Samples

Minimal Residual Disease Assessed by NPM1 Mutation Specific RQ-PCR Is the Most Relevant Prognostic Parameter in NPM1-Mutated AML and Highly Useful to Guide Therapy

Nucleophosmin gene mutations are predictors of favorable prognosis in acute myelogenous leukemia with a normal karyotype

Nucleophosmin Gene Mutations Are Predictors of Favourable Prognosis in Acute Myeloid Leukemia with a Normal Kayotype and Can Be Used as a New Marker for Quantitative PCR To Detect Minimal Residual Disease.

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only